Accredited Investors’s GSK GSK Stock Holding History

Accredited Investors’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-22,287	Closed	-$1.13M	–	120
2017 Q3	$1.13M	Buy	+22,287	New	+$1.13M	0.31%	33

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Accredited Investors's GSK Position: Q4 2017 in Review

Accredited Investors sold out of GSK (GSK) in Q4 2017, closing a stake of 22,287 shares — an estimated $1.13M sold.

Accredited Investors first reported a position in GSK in Q3 2017 and held it in 1 quarter. The position peaked at $1.13M in Q3 2017. 763 funds tracked by Wall St. Rank hold GSK as of Q4 2017.

Accredited Investors reported no remaining GSK position as of Q4 2017 after selling out during the quarter.
Accredited Investors sold 22,287 GSK shares in Q4 2017, an estimated $1.13M.
Accredited Investors first reported a position in GSK in Q3 2017 and held it in 1 quarter.
Accredited Investors's GSK position peaked at $1.13M in Q3 2017.
763 funds tracked by Wall St. Rank held GSK as of Q4 2017.

Based on Accredited Investors's 13F filing for Q4 2017, filed 17 Jan 2018.